ArticleBMC cardiovascular disorders2025
A predictive model for heart failure with preserved ejection fraction following acute myocardial infarction: the HFpEF-AMI score.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early SGLT2 Inhibitor Therapy in Acute Coronary Syndrome: Mitigating Adverse Remodeling in High-Risk Phenotypes-A Real-World Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Sodium-glucose cotransporter 2 inhibitors reduce new-onset heart failure and death after myocardial infarction with a preserved ejection fraction following coronary intervention.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure with preserved ejection fraction (HFpEF) is a common yet under-recognized complication following acute myocardial infarction (AMI), particularly after primary percutaneous coronary intervention (PCI). Early identification of at-risk patients remains a clinical challenge.
methodsWe retrospectively analyzed 458 first-episode AMI patients who underwent emergency PCI at a single center. Patients were stratified into HFpEF (n = 107) and non-heart failure (non-HF) (n = 351) groups based on the 2021 European Society of Cardiology diagnostic criteria. Clinical variables, laboratory markers, echocardiographic parameters, and coronary angiography findings were compared. Logistic regression identified independent predictors of HFpEF, and a predictive model-the Heart Failure with Preserved Ejection Fraction-Acute Myocardial Infarction Score (HFpEF-AMI Score)-was developed and evaluated.
resultsAmong 458 first-episode AMI patients undergoing emergency PCI, 107 (23.4%) developed HFpEF during hospitalization. Multivariate logistic regression identified four independent predictors of HFpEF after PCI: elevated D-dimer (>184.3 ng/mL; odds ratio [OR] 1.626, 95% confidence interval [CI] 1.466-2.771, p < 0.001), peak N-terminal pro-B-type natriuretic peptide (NT-proBNP) (>2640.11 pg/mL; OR 3.391, 95% CI 2.030-5.273, p < 0.001), increased left ventricular mass index (LVMI) (>105.91 g/m²; OR 2.057, 95% CI 1.152-3.833, p = 0.012), and involvement of the left anterior descending artery (LAD) as the infarct-related artery (IRA) (OR 4.737, 95% CI 2.363-10.545, p < 0.001). Using receiver operating characteristic (ROC) analysis, the HFpEF-AMI Score integrating these four predictors demonstrated excellent discriminatory performance, with an area under the curve (AUC) of 0.882 (95% CI: 0.849-0.910). At an optimal cut-off logit(P) ≥ 0.322, the model achieved a sensitivity of 74.8% and specificity of 86.6%. During 2-year follow-up, HFpEF patients had significantly higher rates of major adverse cardiovascular and cerebrovascular events (MACCE: 19.6% vs. 6.0%) and heart failure-related rehospitalizations (18.7% vs. 4.3%; both p < 0.001).
conclusionThe HFpEF-AMI Score is a novel and clinically applicable tool for early identification of patients at risk of developing HFpEF after AMI. Incorporating routine laboratory and angiographic parameters, this score may assist in risk stratification and long-term prognostic assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.